Dr. Frank A. Sinicrope, MD

Dr. Sinicrope practices at Mayo Clinic Hospital, Saint Marys Campus in Rochester, Minnesota, part of Mayo Clinic.

Dr. Sinicrope's NPI, 1144200353, was assigned on January 23, 2006. Dr. Sinicrope graduated from Pritzker School of Medicine in 1985. Dr. Sinicrope holds Minnesota license 45128.

Dr. Sinicrope's primary practice is Mayo Clinic Hospital, Saint Marys Campus, at 1216 Second Street Southwest, Rochester, MN 55902 in Olmsted County. The practice phone is (507) 255-5123.

Dr. Sinicrope's primary practice is Mayo Clinic Hospital, Saint Marys Campus in Rochester, Minnesota, part of Mayo Clinic. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Sinicrope to 1 more hospice, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sinicrope practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Sinicrope's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Sinicrope is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Sinicrope's licenses on file in 4 states: Minnesota, California, Texas and Illinois.

Dmand AI lists colonoscopy, intestinal or bowel obstruction and upper GI endoscopy among the conditions Dr. Sinicrope treats.

CMS data shows 4,702 Medicare services from Dr. Sinicrope across 17 procedure codes in 2024, for 185 Medicare patients. Medicare paid $27,295 for them. Every service was in an office.

CMS counts 185 Medicare patients who saw Dr. Sinicrope in 2024. The largest group is 65 to 74, with 96 patients. 66% of them have cancer, and 62% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sinicrope's median patient age at 65, with 48% women.

In 2024, Dr. Sinicrope wrote 115 Medicare Part D claims for 37 patients. 86% of them were for generic drugs. CMS names the drug for 27 of them, across 2 drugs with 11 or more claims each, at $200 in total drug cost. In 2022, CMS named 12 claims across 1 drug.

Dr. Sinicrope accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sinicrope as offering telehealth.

Dmand AI links 188 papers to Dr. Sinicrope, published from 2006 to 2024. 2020 was the busiest year, with 12. The most frequent topics are Colonic Neoplasms, Colorectal Neoplasms and Fluorouracil. Dr. Sinicrope has published most often in Clin Cancer Res. Dr. Sinicrope's most frequent co-authors are Steven R. Alberts, MD, Zhaohui Jin, MD and Morton S. Kahlenberg, MD.

Dmand AI links Dr. Sinicrope to 7 clinical trials, 4 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Colorectal Neoplasms, Colonic Neoplasms and Rectal Diseases. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 70 general payments to Dr. Sinicrope from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 60% of the total. Genentech, Inc. paid the most, $28,089.

Dr. Sinicrope graduated from Pritzker School of Medicine in 1985. Dr. Sinicrope is a member of ASCO.

Dr. Sinicrope is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.